Get started
Author

Zhihai Wu

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit
2019 · Jie Wang, Keke Fei, et al. · mAbs · 149
Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity
2020 · Yan Wang, Haiqing Ni, et al. · Cancer Immunology Immunotherapy · 116
PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity
2021 · Haiping Jiang, Haiqing Ni, et al. · OncoImmunology · 102
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
2023 · Weiwei Wu, Tiongsun Chia, et al. · Nature Cancer · 86
Recent advances in chiral liquid chromatography stationary phases for pharmaceutical analysis
2023 · Huifeng Liu, Zhihai Wu, et al. · Journal of Chromatography A · 85
Enhanced adsorption and synergistic photocatalytic degradation of tetracycline by MOF-801/GO composites via solvothermal synthesis
2022 · Zhihai Wu, Ziying Chen, et al. · Environmental Science Nano · 52
Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity
2021 · Yunqian Qiao, Yangmin Qiu, et al. · Nature Communications · 43
PDF
Comparative study of CTX-II, Zn2+, and Ca2+ from the urine for knee osteoarthritis patients and healthy individuals
2017 · Linwei Xin, Zhihai Wu, et al. · Medicine · 32
Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody
2021 · Haiqing Ni, Lei Cao, et al. · Cancer Immunology Immunotherapy · 30
Development and characterization of a novel anti-OX40 antibody for potent immune activation
2020 · Zhihui Kuang, Hua Jing, et al. · Cancer Immunology Immunotherapy · 29
A Novel Bispecific Antibody with PD-L1–assisted OX40 Activation for Cancer Treatment
2020 · Zhihui Kuang, Pu Pu, et al. · Molecular Cancer Therapeutics · 26
PDF
Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance
2022 · Jia Zou, Li Li, et al. · Journal of Clinical Investigation · 22
PDF
Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study
2024 · Chenyu Mao, Anwen Xiong, et al. · Journal of Hematology & Oncology · 19
PDF
IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis
2020 · Li Li, Zhihai Wu, et al. · International Immunopharmacology · 14
Pharmacology, pharmacokinetics, and toxicity characterization of a novel anti-CD73 therapeutic antibody IBI325 for cancer immunotherapy
2022 · Ying Zhou, Haoran Shen, et al. · International Journal of Biological Macromolecules · 11
Recent advances in freeze-drying technologies for mRNA vaccines against infectious diseases
2025 · Jinghu Lou, Zhineng Wu, et al. · International Journal of Pharmaceutics · 10
Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies
2022 · Jie Wang, Chen Li, et al. · Cancer Immunology Immunotherapy · 10
A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism
2025 · Huan Zhang, Fufan He, et al. · Molecular Cancer Therapeutics · 9
Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity
2022 · Huisi Liu, Weiwei Wu, et al. · Cell Reports Medicine · 6
Characterization of a novel anti-PVRIG antibody with Fc-competent function that exerts strong antitumor effects via NK activation in preclinical models
2024 · Hongyu Xue, Zhimin Zhang, et al. · Cancer Immunology Immunotherapy · 5
PDF
Effects of different immunosuppressive drugs on the periodontal status and changes in periodontal pathogenic bacterial flora in rheumatoid arthritis patients
2021 · Zhihai Wu, Xuguang Yang, et al. · Tropical Journal of Pharmaceutical Research · 5
PDF
Fault-tolerant finite-time dynamical consensus of double-integrator multi-agent systems with partial agents subject to synchronous self-sensing function failure
2022 · Zhi-Hai Wu, Lin-Bo Xie · Chinese Physics B · 4
Abstract 344: IBI3014, a TROP2xPD-L1 bi-specific ADC integrating ADC killing with checkpoint blockade within one molecule, exhibits promising efficacy and safety in preclinical models
2025 · Xiguang Zhang, Yanping Jin, et al. · Cancer Research · 3
Effectiveness and safety of brucea javanica oil assisted TACE versus TACE in the treatment of liver cancer: a systematic review and meta-analysis of randomized controlled trials
2024 · Zhi-Hai Wu, Hai-Feng Zhang, et al. · Frontiers in Pharmacology · 3
IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma
2022 · Keke Fei, Haiqing Ni, et al. · Cancer Letters · 3
Works count: 49
Citation count: 879
H-index: 14
I10-index: 17
Year
Topic
Type